You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNimodipine
Accession NumberDB00393  (APRD00612)
TypeSmall Molecule
GroupsApproved
DescriptionNimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Structure
Thumb
Synonyms
2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-beta-methoxyethyl ester 5-isopropyl ester
BAY e 9736
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
Nimodipine
Nimodipino
Nimodipinum
Nimotop
Periplum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nimotoptablet30 mgoralBayer Inc2009-07-24Not applicableCanada
Nimotop - Cap 30mgcapsule30 mgoralBayer Inc1989-12-312009-08-06Canada
Nimotop Cap 30mgcapsule30 mgoralMiles Canada Inc. Pharmaceutical Division1989-12-311996-10-02Canada
Nimotop I.V.-0.2mg/mlliquid.2 mgintravenousBayer Inc1996-10-082000-09-19Canada
Nimotop IV 0.2mg/mlliquid0.2 mgintravenousMiles Canada Inc. Pharmaceutical Division1992-12-312000-08-01Canada
Nymalizesolution60 mg/20mLoralArbor Pharmaceuticals2013-06-03Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nimodipinecapsule, liquid filled30 mg/1oralCardinal Health2008-03-21Not applicableUs
Nimodipinecapsule, liquid filled30 mg/1oralHeritage2008-03-21Not applicableUs
Nimodipinecapsule30 mg/1oralANI Pharmaceuticals, Inc.2015-11-01Not applicableUs
Nimodipinecapsule, liquid filled30 mg/1oralMajor Pharmaceuticals2015-01-01Not applicableUs
Nimodipinecapsule30 mg/1oralCardinal Health2007-06-28Not applicableUs
Nimodipinecapsule, liquid filled30 mg/1oralAscend Laboratories, LLC2015-01-01Not applicableUs
Nimodipinecapsule30 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2007-06-28Not applicableUs
Nimodipinecapsule, liquid filled30 mg/1oralAmerican Health Packaging2015-02-15Not applicableUs
Nimodipinecapsule, liquid filled30 mg/1oralGolden State Medical Supply, Inc.2008-03-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PeriplumNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII57WA9QZ5WH
CAS number66085-59-4
WeightAverage: 418.4403
Monoisotopic: 418.174001196
Chemical FormulaC21H26N2O7
InChI KeyInChIKey=UIAGMCDKSXEBJQ-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
IUPAC Name
3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Ether
  • Enamine
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
PharmacodynamicsNimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier.
Mechanism of actionAlthough the precise mechanism of action is not known, nimodipine blocks intracellular influx of calcium through voltage-dependent and receptor-operated slow calcium channels across the membranes of myocardial, vascular smooth muscle, and neuronal cells. Nimodipine binds specifically to L-type voltage-gated calcium channels. The inhibition of calcium ion transfer results in the inhibition of vascular smooth muscle contraction. Evidence suggests that the dilation of small cerebral resistance vessels, with a resultant increase in collateral circulation, and/or a direct effect involving the prevention of calcium overload in neurons may be responsible for nimodipine's clinical effect in patients with subarachnoid hemorrhage.
Related Articles
AbsorptionIn humans, nimodipine is rapidly absorbed after oral administration, and peak concentrations are generally attained within one hour. Bioavailability is 100% following intravenous administration and 3-30% following oral administration due to extensive first-pass metabolism.
Volume of distributionNot Available
Protein binding95% bound to plasma protein
Metabolism

Hepatic metabolism via CYP 3A4.

Route of eliminationNimodipine is eliminated almost exclusively in the form of metabolites and less than 1% is recovered in the urine as unchanged drug. Numerous metabolites, all of which are either inactive or considerably less active than the parent compound, have been identified.
Half life1.7-9 hours
ClearanceNot Available
ToxicitySymptoms of overdosage would be expected to be related to cardiovascular effects such as excessive peripheral vasodilation with marked systemic hypotension.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nimodipine Action PathwayDrug actionSMP00380
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9387
Blood Brain Barrier-0.9358
Caco-2 permeable-0.5838
P-glycoprotein substrateSubstrate0.752
P-glycoprotein inhibitor IInhibitor0.9287
P-glycoprotein inhibitor IIInhibitor0.9098
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8151
CYP450 2D6 substrateNon-substrate0.9118
CYP450 3A4 substrateSubstrate0.7571
CYP450 1A2 substrateInhibitor0.9108
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.8248
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8557
Ames testNon AMES toxic0.5976
CarcinogenicityNon-carcinogens0.6953
BiodegradationNot ready biodegradable0.8797
Rat acute toxicity2.5326 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6468
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Banner pharmacaps inc
  • Barr laboratories inc
  • Sun pharmaceutical industries inc
  • Bayer pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Capsuleoral30 mg/1
Capsule, liquid filledoral30 mg/1
Tabletoral30 mg
Capsuleoral30 mg
Liquidintravenous.2 mg
Liquidintravenous0.2 mg
Solutionoral60 mg/20mL
Prices
Unit descriptionCostUnit
NiMODipine 100 30 mg capsule Box952.07USD box
Nimotop 30 mg capsule9.87USD capsule
Nimodipine 30 mg capsule9.69USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point125 °CNot Available
logP3.05MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP3.41ALOGPS
logP2.54ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)5.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area119.68 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity112.38 m3·mol-1ChemAxon
Polarizability43.17 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Janjua N, Mayer SA: Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care. 2003 Apr;9(2):113-9. [PubMed:12657973 ]
  2. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR: Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983 Mar 17;308(11):619-24. [PubMed:6338383 ]
  3. Belfort MA, Anthony J, Saade GR, Allen JC Jr: A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003 Jan 23;348(4):304-11. [PubMed:12540643 ]
  4. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  5. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F: Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens. 2008 Nov;30(8):744-66. doi: 10.1080/10641960802580232. [PubMed:19021025 ]
  6. Vergouwen MD, Vermeulen M, Roos YB: Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review. Lancet Neurol. 2006 Dec;5(12):1029-32. [PubMed:17110283 ]
External Links
ATC CodesC08CA06
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelDownload (504 KB)
MSDSDownload (73.3 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nimodipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nimodipine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nimodipine.
AcebutololNimodipine may increase the hypotensive activities of Acebutolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Acetazolamide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nimodipine.
AliskirenNimodipine may increase the hypotensive activities of Aliskiren.
AlprazolamThe serum concentration of Nimodipine can be increased when it is combined with Alprazolam.
AlprenololNimodipine may increase the hypotensive activities of Alprenolol.
AmbrisentanNimodipine may increase the hypotensive activities of Ambrisentan.
AmifostineNimodipine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Amiloride.
AmiodaroneThe serum concentration of Nimodipine can be increased when it is combined with Amiodarone.
AmlodipineThe serum concentration of Nimodipine can be increased when it is combined with Amlodipine.
AmlodipineNimodipine may increase the hypotensive activities of Amlodipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Nimodipine.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nimodipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimodipine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Nimodipine is combined with Amyl Nitrite.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nimodipine.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nimodipine.
ApraclonidineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Apraclonidine.
AprepitantThe serum concentration of Nimodipine can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the hypotensive activities of Nimodipine.
ArmodafinilThe serum concentration of Nimodipine can be decreased when it is combined with Armodafinil.
ArtemetherThe serum concentration of Nimodipine can be decreased when it is combined with Artemether.
AtazanavirThe serum concentration of Nimodipine can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Nimodipine.
AtomoxetineThe serum concentration of Nimodipine can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Nimodipine can be increased when it is combined with Atorvastatin.
AtosibanThe risk or severity of adverse effects can be increased when Nimodipine is combined with Atosiban.
Atracurium besylateNimodipine may increase the neuromuscular blocking activities of Atracurium besylate.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Azilsartan medoxomil.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nimodipine.
BarbitalBarbital may increase the hypotensive activities of Nimodipine.
BenazeprilNimodipine may increase the hypotensive activities of Benazepril.
BendroflumethiazideNimodipine may increase the hypotensive activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Nimodipine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nimodipine.
BepridilNimodipine may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Nimodipine.
BethanidineBethanidine may increase the hypotensive activities of Nimodipine.
BexaroteneThe serum concentration of Nimodipine can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Nimodipine can be increased when it is combined with Bicalutamide.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nimodipine.
BimatoprostNimodipine may increase the hypotensive activities of Bimatoprost.
BisoprololNimodipine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Nimodipine can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Nimodipine can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Nimodipine can be decreased when it is combined with Bosentan.
BosentanNimodipine may increase the hypotensive activities of Bosentan.
BretyliumNimodipine may increase the hypotensive activities of Bretylium.
BrimonidineNimodipine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Nimodipine.
BumetanideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Bumetanide.
BupranololNimodipine may increase the hypotensive activities of Bupranolol.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nimodipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nimodipine.
CalcitriolThe serum concentration of Nimodipine can be decreased when it is combined with Calcitriol.
CanagliflozinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Canagliflozin.
CandesartanNimodipine may increase the hypotensive activities of Candesartan.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nimodipine.
CandoxatrilNimodipine may increase the hypotensive activities of Candoxatril.
CaptoprilNimodipine may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Nimodipine can be decreased when it is combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Nimodipine.
CarteololNimodipine may increase the hypotensive activities of Carteolol.
CarvedilolNimodipine may increase the hypotensive activities of Carvedilol.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimodipine.
CeliprololNimodipine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Nimodipine can be increased when it is combined with Ceritinib.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nimodipine.
ChlorothiazideNimodipine may increase the hypotensive activities of Chlorothiazide.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nimodipine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nimodipine.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimodipine.
CilazaprilNimodipine may increase the hypotensive activities of Cilazapril.
CilostazolThe serum concentration of Nimodipine can be increased when it is combined with Cilostazol.
CimetidineThe serum concentration of Nimodipine can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Nimodipine can be increased when it is combined with Ciprofloxacin.
ClarithromycinThe serum concentration of Nimodipine can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Nimodipine can be increased when it is combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clevidipine.
ClobazamThe serum concentration of Nimodipine can be decreased when it is combined with Clobazam.
ClonidineNimodipine may increase the hypotensive activities of Clonidine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimodipine.
ClotrimazoleThe serum concentration of Nimodipine can be increased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Nimodipine can be increased when it is combined with Cobicistat.
ConivaptanThe serum concentration of Nimodipine can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Nimodipine can be increased when it is combined with Crizotinib.
CryptenamineNimodipine may increase the hypotensive activities of Cryptenamine.
CyclosporineThe serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.
CyclothiazideNimodipine may increase the hypotensive activities of Cyclothiazide.
DabrafenibThe serum concentration of Nimodipine can be decreased when it is combined with Dabrafenib.
DalfopristinThe serum concentration of Nimodipine can be increased when it is combined with Dalfopristin.
DanazolThe serum concentration of Nimodipine can be increased when it is combined with Danazol.
DapagliflozinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nimodipine.
DarunavirThe serum concentration of Nimodipine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Nimodipine can be increased when it is combined with Dasatinib.
DebrisoquinNimodipine may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nimodipine.
DeferasiroxThe serum concentration of Nimodipine can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Nimodipine can be increased when it is combined with Delavirdine.
DeserpidineNimodipine may increase the hypotensive activities of Deserpidine.
DesvenlafaxineThe serum concentration of Nimodipine can be decreased when it is combined with Desvenlafaxine.
DexamethasoneThe serum concentration of Nimodipine can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dexmedetomidine.
DiazoxideDiazoxide may increase the hypotensive activities of Nimodipine.
DiclofenamideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Diclofenamide.
DicloxacillinThe serum concentration of Nimodipine can be decreased when it is combined with Dicloxacillin.
DihydroergotamineThe serum concentration of Nimodipine can be increased when it is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Nimodipine can be increased when it is combined with Diltiazem.
DiltiazemNimodipine may increase the hypotensive activities of Diltiazem.
DinutuximabThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dipyridamole.
DorzolamideNimodipine may increase the hypotensive activities of Dorzolamide.
DoxazosinNimodipine may increase the hypotensive activities of Doxazosin.
DoxycyclineThe serum concentration of Nimodipine can be increased when it is combined with Doxycycline.
DronedaroneThe serum concentration of Nimodipine can be increased when it is combined with Dronedarone.
DrospirenoneThe serum concentration of Nimodipine can be decreased when it is combined with Drospirenone.
DuloxetineNimodipine may increase the orthostatic hypotensive activities of Duloxetine.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nimodipine.
EfavirenzThe serum concentration of Nimodipine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nimodipine.
EfonidipineNimodipine may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Empagliflozin.
EnalaprilNimodipine may increase the hypotensive activities of Enalapril.
EnalaprilatNimodipine may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Nimodipine can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Eplerenone.
EpoprostenolNimodipine may increase the hypotensive activities of Epoprostenol.
EprosartanNimodipine may increase the hypotensive activities of Eprosartan.
ErythromycinThe serum concentration of Nimodipine can be increased when it is combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Nimodipine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nimodipine.
EstradiolThe serum concentration of Nimodipine can be decreased when it is combined with Estradiol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.
EtravirineThe serum concentration of Nimodipine can be decreased when it is combined with Etravirine.
ExemestaneThe serum concentration of Nimodipine can be decreased when it is combined with Exemestane.
FelbamateThe serum concentration of Nimodipine can be decreased when it is combined with Felbamate.
FelodipineNimodipine may increase the hypotensive activities of Felodipine.
FenoldopamNimodipine may increase the hypotensive activities of Fenoldopam.
FluconazoleThe serum concentration of Nimodipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nimodipine.
FluoxetineThe serum concentration of Nimodipine can be increased when it is combined with Fluoxetine.
FluvoxamineThe serum concentration of Nimodipine can be increased when it is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Nimodipine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Nimodipine can be increased when it is combined with Fosaprepitant.
FosinoprilNimodipine may increase the hypotensive activities of Fosinopril.
FosphenytoinThe serum concentration of Nimodipine can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nimodipine.
FurazolidoneFurazolidone may increase the hypotensive activities of Nimodipine.
FurosemideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Furosemide.
Fusidic AcidThe serum concentration of Nimodipine can be increased when it is combined with Fusidic Acid.
Glycerol PhenylbutyrateThe serum concentration of Nimodipine can be increased when it is combined with Glycerol Phenylbutyrate.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nimodipine.
GriseofulvinThe serum concentration of Nimodipine can be decreased when it is combined with Griseofulvin.
GuanabenzNimodipine may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Nimodipine.
GuanethidineNimodipine may increase the hypotensive activities of Guanethidine.
GuanfacineNimodipine may increase the hypotensive activities of Guanfacine.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nimodipine.
HexamethoniumNimodipine may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nimodipine.
HexobarbitalHexobarbital may increase the hypotensive activities of Nimodipine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Nimodipine.
HydralazineNimodipine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideNimodipine may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Nimodipine can be decreased when it is combined with Hydrocortisone.
HydroflumethiazideNimodipine may increase the hypotensive activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Nimodipine can be increased when it is combined with Idelalisib.
IloperidoneThe serum concentration of Nimodipine can be increased when it is combined with Iloperidone.
IloprostIloprost may increase the hypotensive activities of Nimodipine.
ImatinibThe serum concentration of Nimodipine can be increased when it is combined with Imatinib.
IndapamideNimodipine may increase the hypotensive activities of Indapamide.
IndenololNimodipine may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Nimodipine can be increased when it is combined with Indinavir.
IndoraminNimodipine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Nimodipine.
IproniazidIproniazid may increase the hypotensive activities of Nimodipine.
IrbesartanNimodipine may increase the hypotensive activities of Irbesartan.
IsavuconazoniumThe serum concentration of Nimodipine can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nimodipine.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nimodipine.
IsoniazidThe serum concentration of Nimodipine can be increased when it is combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isoxsuprine.
IsradipineThe serum concentration of Nimodipine can be increased when it is combined with Isradipine.
IsradipineNimodipine may increase the hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Nimodipine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Nimodipine can be increased when it is combined with Ivacaftor.
KetoconazoleThe serum concentration of Nimodipine can be increased when it is combined with Ketoconazole.
LabetalolNimodipine may increase the hypotensive activities of Labetalol.
LacidipineNimodipine may increase the hypotensive activities of Lacidipine.
LapatinibThe serum concentration of Nimodipine can be increased when it is combined with Lapatinib.
LatanoprostNimodipine may increase the hypotensive activities of Latanoprost.
LercanidipineNimodipine may increase the hypotensive activities of Lercanidipine.
LevobunololThe risk or severity of adverse effects can be increased when Nimodipine is combined with Levobunolol.
LevodopaNimodipine may increase the orthostatic hypotensive activities of Levodopa.
LisinoprilNimodipine may increase the hypotensive activities of Lisinopril.
LofexidineNimodipine may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Nimodipine can be increased when it is combined with Lomitapide.
LopinavirThe serum concentration of Nimodipine can be increased when it is combined with Lopinavir.
LosartanNimodipine may increase the hypotensive activities of Losartan.
LovastatinThe serum concentration of Nimodipine can be increased when it is combined with Lovastatin.
LuliconazoleThe serum concentration of Nimodipine can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Nimodipine can be decreased when it is combined with Lumefantrine.
LurasidoneThe serum concentration of Nimodipine can be increased when it is combined with Lurasidone.
MacitentanNimodipine may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium Sulfate.
ManidipineNimodipine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Nimodipine is combined with Mannitol.
MebanazineMebanazine may increase the hypotensive activities of Nimodipine.
MecamylamineNimodipine may increase the hypotensive activities of Mecamylamine.
Medroxyprogesterone acetateThe serum concentration of Nimodipine can be decreased when it is combined with Medroxyprogesterone acetate.
MethazolamideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Nimodipine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nimodipine.
MethyldopaNimodipine may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Nimodipine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nimodipine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nimodipine.
MetipranololNimodipine may increase the hypotensive activities of Metipranolol.
MetolazoneNimodipine may increase the hypotensive activities of Metolazone.
MetoprololMetoprolol may increase the hypotensive activities of Nimodipine.
MetyraponeThe serum concentration of Nimodipine can be decreased when it is combined with Metyrapone.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nimodipine.
MibefradilNimodipine may increase the hypotensive activities of Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nimodipine.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nimodipine.
MifepristoneThe serum concentration of Nimodipine can be increased when it is combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nimodipine.
MinaprineMinaprine may increase the hypotensive activities of Nimodipine.
MinoxidilMinoxidil may increase the hypotensive activities of Nimodipine.
MitotaneThe serum concentration of Nimodipine can be decreased when it is combined with Mitotane.
MivacuriumNimodipine may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Nimodipine.
ModafinilThe serum concentration of Nimodipine can be decreased when it is combined with Modafinil.
MoexiprilNimodipine may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Nimodipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nimodipine.
MoxonidineNimodipine may increase the hypotensive activities of Moxonidine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nimodipine.
NadololNimodipine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Nimodipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nimodipine.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nimodipine.
NebivololNimodipine may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nimodipine can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nimodipine can be increased when it is combined with Nelfinavir.
NesiritideThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nesiritide.
NetupitantThe serum concentration of Nimodipine can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nimodipine can be decreased when it is combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Nimodipine.
NicardipineThe serum concentration of Nimodipine can be increased when it is combined with Nicardipine.
NicardipineNimodipine may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Nimodipine.
NifedipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nifedipine.
NiguldipineNimodipine may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nimodipine can be increased when it is combined with Nilotinib.
NilvadipineNimodipine may increase the hypotensive activities of Nilvadipine.
NisoldipineNimodipine may increase the hypotensive activities of Nisoldipine.
NitrendipineNimodipine may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nitroglycerin.
NitroprussideNimodipine may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nimodipine.
NorgestimateThe serum concentration of Nimodipine can be decreased when it is combined with Norgestimate.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nimodipine.
ObinutuzumabNimodipine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Nimodipine.
OlaparibThe serum concentration of Nimodipine can be increased when it is combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Nimodipine.
OmapatrilatNimodipine may increase the hypotensive activities of Omapatrilat.
OritavancinThe serum concentration of Nimodipine can be decreased when it is combined with Oritavancin.
OsimertinibThe serum concentration of Nimodipine can be increased when it is combined with Osimertinib.
OxcarbazepineThe serum concentration of Nimodipine can be decreased when it is combined with Oxcarbazepine.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nimodipine.
OxprenololNimodipine may increase the hypotensive activities of Oxprenolol.
PaclitaxelThe serum concentration of Nimodipine can be decreased when it is combined with Paclitaxel.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nimodipine.
PalbociclibThe serum concentration of Nimodipine can be increased when it is combined with Palbociclib.
PapaverineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Papaverine.
PargylineNimodipine may increase the hypotensive activities of Pargyline.
PazopanibThe serum concentration of Nimodipine can be increased when it is combined with Pazopanib.
PenbutololNimodipine may increase the hypotensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimodipine.
PentobarbitalThe serum concentration of Nimodipine can be decreased when it is combined with Pentobarbital.
PentoliniumNimodipine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nimodipine.
PerampanelThe serum concentration of Nimodipine can be decreased when it is combined with Perampanel.
PerindoprilNimodipine may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Nimodipine.
PheniprazinePheniprazine may increase the hypotensive activities of Nimodipine.
PhenobarbitalThe serum concentration of Nimodipine can be decreased when it is combined with Phenobarbital.
PhenoxybenzamineNimodipine may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nimodipine.
PhentolamineNimodipine may increase the hypotensive activities of Phentolamine.
PhenytoinThe serum concentration of Nimodipine can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nimodipine.
PinacidilNimodipine may increase the hypotensive activities of Pinacidil.
PindololNimodipine may increase the hypotensive activities of Pindolol.
PioglitazoneThe serum concentration of Nimodipine can be decreased when it is combined with Pioglitazone.
PirlindolePirlindole may increase the hypotensive activities of Nimodipine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Nimodipine.
PolythiazideNimodipine may increase the hypotensive activities of Polythiazide.
PosaconazoleThe serum concentration of Nimodipine can be increased when it is combined with Posaconazole.
PrazosinNimodipine may increase the hypotensive activities of Prazosin.
PrednisoneThe serum concentration of Nimodipine can be decreased when it is combined with Prednisone.
PrimidoneThe serum concentration of Nimodipine can be decreased when it is combined with Primidone.
PropofolThe serum concentration of Nimodipine can be increased when it is combined with Propofol.
PropranololNimodipine may increase the hypotensive activities of Propranolol.
QuetiapineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Quetiapine.
QuinaprilNimodipine may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Nimodipine can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Nimodipine.
QuinupristinThe serum concentration of Nimodipine can be increased when it is combined with Quinupristin.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nimodipine.
RamiprilRamipril may increase the hypotensive activities of Nimodipine.
RanolazineThe serum concentration of Nimodipine can be increased when it is combined with Ranolazine.
RapacuroniumNimodipine may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Nimodipine.
RemikirenRemikiren may increase the hypotensive activities of Nimodipine.
RescinnamineNimodipine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Nimodipine.
RifabutinThe serum concentration of Nimodipine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Nimodipine can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Nimodipine can be decreased when it is combined with Rifapentine.
RiociguatNimodipine may increase the hypotensive activities of Riociguat.
RisperidoneNimodipine may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Nimodipine can be increased when it is combined with Ritonavir.
RituximabNimodipine may increase the hypotensive activities of Rituximab.
RufinamideThe serum concentration of Nimodipine can be decreased when it is combined with Rufinamide.
SafrazineSafrazine may increase the hypotensive activities of Nimodipine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nimodipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nimodipine.
SaprisartanNimodipine may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Nimodipine can be increased when it is combined with Saquinavir.
SecobarbitalSecobarbital may increase the hypotensive activities of Nimodipine.
SelegilineSelegiline may increase the hypotensive activities of Nimodipine.
SelexipagNimodipine may increase the hypotensive activities of Selexipag.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nimodipine.
SildenafilThe serum concentration of Nimodipine can be increased when it is combined with Sildenafil.
SilodosinSilodosin may increase the hypotensive activities of Nimodipine.
SiltuximabThe serum concentration of Nimodipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Nimodipine can be increased when it is combined with Simeprevir.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nimodipine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nimodipine.
SitaxentanNimodipine may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sotalol.
SpiraprilNimodipine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Nimodipine is combined with Spironolactone.
St. John's WortThe serum concentration of Nimodipine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Nimodipine can be increased when it is combined with Stiripentol.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nimodipine.
SulfisoxazoleThe serum concentration of Nimodipine can be increased when it is combined with Sulfisoxazole.
TadalafilTadalafil may increase the antihypertensive activities of Nimodipine.
TamsulosinTamsulosin may increase the hypotensive activities of Nimodipine.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nimodipine.
TelaprevirThe serum concentration of Nimodipine can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Nimodipine can be increased when it is combined with Telithromycin.
TelmisartanNimodipine may increase the hypotensive activities of Telmisartan.
TemocaprilNimodipine may increase the hypotensive activities of Temocapril.
TerazosinTerazosin may increase the hypotensive activities of Nimodipine.
TerazosinThe risk or severity of adverse effects can be increased when Nimodipine is combined with Terazosin.
TerbinafineThe serum concentration of Nimodipine can be decreased when it is combined with Terbinafine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nimodipine.
TerlipressinNimodipine may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Nimodipine.
ThiopentalThiopental may increase the hypotensive activities of Nimodipine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nimodipine.
TiboloneNimodipine may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Nimodipine can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Nimodipine can be increased when it is combined with Ticlopidine.
TicrynafenNimodipine may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Nimodipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nimodipine.
TizanidineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Tizanidine.
TocilizumabThe serum concentration of Nimodipine can be decreased when it is combined with Tocilizumab.
TolazolineNimodipine may increase the hypotensive activities of Tolazoline.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nimodipine.
ToloxatoneToloxatone may increase the hypotensive activities of Nimodipine.
TopiramateThe serum concentration of Nimodipine can be decreased when it is combined with Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Nimodipine.
TrametinibThe serum concentration of Nimodipine can be decreased when it is combined with Trametinib.
TrandolaprilNimodipine may increase the hypotensive activities of Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nimodipine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Nimodipine.
TravoprostTravoprost may increase the hypotensive activities of Nimodipine.
TreprostinilTreprostinil may increase the hypotensive activities of Nimodipine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nimodipine.
TrichlormethiazideNimodipine may increase the hypotensive activities of Trichlormethiazide.
TrimazosinNimodipine may increase the hypotensive activities of Trimazosin.
TrimethaphanNimodipine may increase the hypotensive activities of Trimethaphan.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nimodipine.
UdenafilUdenafil may increase the antihypertensive activities of Nimodipine.
UnoprostoneNimodipine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Nimodipine.
VardenafilVardenafil may increase the antihypertensive activities of Nimodipine.
VemurafenibThe serum concentration of Nimodipine can be decreased when it is combined with Vemurafenib.
VenlafaxineThe serum concentration of Nimodipine can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Nimodipine can be increased when it is combined with Verapamil.
VerapamilThe risk or severity of adverse effects can be increased when Nimodipine is combined with Verapamil.
VoriconazoleThe serum concentration of Nimodipine can be increased when it is combined with Voriconazole.
XylometazolineNimodipine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Nimodipine.
ZiprasidoneThe serum concentration of Nimodipine can be increased when it is combined with Ziprasidone.
Food Interactions
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nimodipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nimodipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take at the same time each day, with or without food, but always in the same manner.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Marchetti C, Usai C: High affinity block by nimodipine of the internal calcium elevation in chronically depolarized rat cerebellar granule neurons. Neurosci Lett. 1996 Mar 29;207(2):77-80. [PubMed:8731425 ]
  3. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  4. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  5. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  6. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  7. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
  8. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
  2. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  3. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  4. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  5. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  6. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1F
Uniprot ID:
O60840
Molecular Weight:
220675.9 Da
References
  1. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  2. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
  2. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  3. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  4. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  5. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  6. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB1
Uniprot ID:
Q02641
Molecular Weight:
65712.995 Da
References
  1. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  2. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  5. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  5. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
  6. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB3
Uniprot ID:
P54284
Molecular Weight:
54531.425 Da
References
  1. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  2. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  5. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB4
Uniprot ID:
O00305
Molecular Weight:
58168.625 Da
References
  1. Weant KA, Ramsey CN 3rd, Cook AM: Role of intraarterial therapy for cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage. Pharmacotherapy. 2010 Apr;30(4):405-17. doi: 10.1592/phco.30.4.405. [PubMed:20334460 ]
  2. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA: Nimodipine enhancement of alpha2 adrenergic modulation of NMDA receptor via a mechanism independent of Ca2+ channel blocking. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4174-80. doi: 10.1167/iovs.09-4613. Epub 2010 Mar 24. [PubMed:20335610 ]
  3. Kim JH, Park IS, Park KB, Kang DH, Hwang SH: Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2009 Sep;46(3):239-44. doi: 10.3340/jkns.2009.46.3.239. Epub 2009 Sep 30. [PubMed:19844625 ]
  4. Kumar R, Mehra R, Ray SB: L-type calcium channel blockers, morphine and pain: Newer insights. Indian J Anaesth. 2010 Mar;54(2):127-31. doi: 10.4103/0019-5049.63652. [PubMed:20661350 ]
  5. Keyrouz SG, Diringer MN: Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11(4):220. [PubMed:17705883 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4. [PubMed:18250364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Transcription regulatory region dna binding
Specific Function:
Ligand-activated transcriptional activator. Binds to the XRE promoter region of genes it activates. Activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene). Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. Involved in cell-cycle regulation. Likely to play an important role in the development and matu...
Gene Name:
AHR
Uniprot ID:
P35869
Molecular Weight:
96146.705 Da
References
  1. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR: Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol. 2007 Jun;71(6):1475-86. Epub 2007 Feb 27. [PubMed:17327465 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23